Oral XXXX for treatment of periocular infantile @entity2695 .

@entity1169 @entity1 @entity940 @entity227 @entity2695 @entity7492 @entity1168 @entity4457
OBJECTIVE: To evaluate the efficacy and adverse effects of oral @entity1169 for treatment of periocular @entity7492 . METHODS: @entity1 were treated with oral @entity1169 3 times daily, with outpatient monitoring of adverse effects. The starting dosage was 0.5 mg/kg/d for 1 week, then 1 mg/kg/d for the following week, then 2 mg/kg/d for the remaining duration of treatment. Serial examinations and external photography documented the size of the @entity2695 . Complete ophthalmic examinations included assessing for @entity4457 with cycloplegic refraction and visual diagnostic testing. @entity4457 was treated with part-time occlusion therapy. RESULTS: Nineteen periocular @entity2695 from 17 @entity1 (71% @entity1 ) were studied. The median age at the start of treatment was 4.5 months (interquartile range, 2.2-5.6 months). The median treatment duration was 6.8 months (interquartile range, 4.1-7.2 months). Treatment with oral @entity1169 reduced the size of all @entity2695 . Median change in the surface area was 61% (interquartile range, 32%-64%) of the original size. Mild rebound growth that did not necessitate retreatment was found in 2 @entity1 (12%). One @entity1 (6%) experienced a benign episode of @entity1168 . Seven @entity1 (41%) had @entity4457 . CONCLUSIONS: Oral @entity1169 for treatment of infantile @entity2695 was effective in all @entity1 , with 33% reduction in @entity940 and 39% reduction in surface area. Vision equalized in all but 1 @entity1 , who receives ongoing @entity4457 therapy. Our results suggest that early treatment with @entity1169 is remarkably effective in treating and preventing @entity227 associated with periocular infantile @entity2695 .
